ReviewDeutsches Arzteblatt international2022
Polymyalgia Rheumatica.
Review in Deutsches Arzteblatt international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Polymyalgia Rheumatica (PMR) and Polymyalgia Rheumatica-like (PMR-like) Manifestations in Cancer Patients Following Treatment with Nivolumab and Pembrolizumab: Methodological Blurred Points Identified Through a Systematic Review of Published Case Reports.Medical sciences (Basel, Switzerland) · 2025Pooled it
- Systematic review to estimate the prevalence of inflammatory rheumatic diseases in Germany.Zeitschrift fur Rheumatologie · 2024Pooled it
- [Systematic review to estimate the prevalence of inflammatory rheumatic diseases in Germany. German version].Zeitschrift fur Rheumatologie · 2023Pooled it
- The epidemiology of inflammatory rheumatic diseases in Germany in a European context: a systematic review to support workforce planning.EULAR rheumatology open · 2026Article
- Small-Molecule Strategies for Polymyalgia Rheumatica and Giant Cell Arteritis in Older Adults.Molecules (Basel, Switzerland) · 2026Review
- Genetic and epidemiological evidence linking respiratory and musculoskeletal diseases: shared risk factors and intervention windows.Respiratory research · 2026Article
- Frequency, diagnosis, and management of polymyalgia rheumatica in Germany-database analysis of medical insurance data.Rheumatology (Oxford, England) · 2025Article
- When can calcium pyrophosphate deposition disease be considered a polymyalgia rheumatica mimicking disease?Reumatologia · 2025Review
- Article
- Why is polymyalgia rheumatica a disease of older adults? Explanations through etiology and pathogenesis: a narrative review.Clinical rheumatology · 2024Review
- [Diagnosis of polymyalgia rheumatica: anamnesis and clinical aspects precede imaging].Zeitschrift fur Rheumatologie · 2023Article
- [18F-FDG-PET/CT in polymyalgia rheumatica-targeted diagnostics in a selected group of patients].Zeitschrift fur Rheumatologie · 2023Article
- In Reply.Deutsches Arzteblatt international · 2023Article
- Prednisolone Is Not a Panacea-B Symptoms Should Be Targeted in Questions.Deutsches Arzteblatt international · 2023Article
- Risk of Blindness.Deutsches Arzteblatt international · 2023Article
- Problems in the Diagnostic Evaluation.Deutsches Arzteblatt international · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolymyalgia rheumatica (PMR) is among the most common inflammatory rheumatic diseases in older adults. Presumed risk factors include female sex, previous infections, and genetic factors. No epidemiological data on PMR in Germany have been available until now.
methodsThis review is based on publications retrieved by a selective literature search in PubMed. Moreover, the administrative incidence and prevalence of PMR in the years 2011-2019 was determined from data of the AOK Baden-Württemberg statutory health insurance carrier for insurees aged 40 and older. In addition, we quantified the number of consultations with physicians involved in the diagnosis.
resultsThe annual age- and sex-standardized incidence and prevalence of PMR from 2011 to 2019 were 18.6/100 000 persons and 138.8/100 000 persons, respectively. The incidence was higher in women than in men (21.8/100 000 vs. 12.8/100 000 persons per year). 60% of the cases were diagnosed in primary care practices. The treatment of PMR with orally administered glucocorticoids usually results in a treatment response within a few days to weeks. Approximately 43% of patients experience recurrent symptoms within a year, requiring adjustment of the glucocorticoid dose. For older patients with impaired physical ability, additional non-pharmacological treatment with exercise programs plays an important role.
conclusionPMR usually takes an uncomplicated course under treatment and can be managed in primary care, but these patients are often multimorbid and require frequent follow-up. Along with research on the etiology of the disease, further studies are needed to identify the risk factors for a chronic course and to evaluate the potential effects of non-pharmacological measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.